Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0AFXBF
ADC Name	Cetuximab-Puromycin
Synonyms	Cetuximab-SATP-Puromycin Click to Show/Hide
Drug Status	Investigative
Indication	In total 1 Indication(s) Triple negative breast cancer [ICD11:2C60-2C65] Investigative
Drug-to-Antibody Ratio	2
Structure
	3D MOL	2D MOL
Antibody Name	Cetuximab		Antibody Info
Antigen Name	Epidermal growth factor receptor (EGFR)		Antigen Info
Payload Name	Puromycin		Payload Info
Therapeutic Target	Ribosome (RB)		Target Info
Linker Name	Succinimidyl acetylthiopropionate (SATP)		Linker Info
Conjugate Type	Puromycin was conjugated to Cetuximab by forming disulfide bonds between thiolated Cetuximab and thiolated Puromycin.

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	37.42	ug/mL	MDA-MB-468 cells	Breast adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	37.42 ug/mL	High EGFR expression (EGFR+++)
Method Description	Cells were seeded into 6-well plates, 500,000 cells/well. One day (24 hours) before treatment, MDA-MB-231 cells are being fasted from FBS. Cells are divided into five different doses of conjugate (5 ug/mL; 10 ug/mL; 20 ug/mL; 40 ug/mL; 80 ug/mL) and one untreated group. They were incubated for 48 hours.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

References

Ref 1	Conjugation of Cetuximab - Puromycin and Its Target-Specific Effect on Triple Negative Breast Cancer Cell Lines. Asian Pac J Cancer Prev. 2022 May 1;23(5):1803-1812.